Visiongain’s latest report, Clinical Trial Supply and Logistics Market for Pharma 2026-2036, provides detailed forecasts and strategic analysis across type, phase, temperature, and therapeutic area segments, including technology trends, trade and supply chain dynamics, and competitive positioning.

The global clinical trial supply and logistics market for pharma is valued at US$7.92 billion in 2026 and is projected to reach US$18.22 billion by 2036, at a CAGR of 8.7% during the forecast period. Growth is driven by rising trial complexity across biologics, cell and gene therapies, and precision medicine, the rapid expansion of decentralised and hybrid trial models, and growing globalisation of clinical research requiring integrated regional supply partners with cold-chain and customs expertise.

Key Market Insights

• The global clinical trial supply and logistics market for pharma will reach US$18.22 billion by 2036, growing at a CAGR of 8.7%
• Growth is driven by biologics pipeline expansion, decentralised trial adoption, and increasing cold-chain requirements across advanced therapy programmes
• Key regions: North America, Europe, Asia Pacific
• Leading companies: Thermo Fisher Scientific, IQVIA, Almac Group, PCI Pharma Services, Parexel
• Key trend: Direct-to-patient logistics transitioning from specialist capability to standard requirement across hybrid and decentralised clinical trial designs

Download Sample Request

Market Drivers

Decentralised and Hybrid Trials Reshaping Distribution Models

Decentralised and hybrid trials are changing how investigational products reach patients. Instead of relying solely on traditional site-based dispensing, sponsors are increasingly using direct-to-patient shipments, home healthcare models, local labs, wearable devices, and remote monitoring. This creates a more patient-friendly trial environment but also adds supply chain complexity, requiring logistics providers to manage smaller and more frequent shipments, tighter delivery windows, patient confidentiality, reverse logistics, and coordination with nursing or home-care services.

The business case for pharma sponsors is clear: decentralised models can reduce patient burden, support enrolment diversity, and improve retention, particularly in rare disease and chronic disease studies. On 28 May 2026, Parexel launched its patient-focused campaign at the 2026 ASCO Annual Meeting, reinforcing its commitment to improving patient access and participation in oncology trials through decentralised and hybrid clinical trial approaches, helping sponsors reduce participant burden while supporting more efficient global clinical development.

Globalisation of Clinical Trials Increasing Demand for Integrated Supply Partners

Pharmaceutical companies are expanding clinical trials across North America, Europe, Asia Pacific, Latin America, and emerging markets to access diverse patient populations, accelerate enrolment, and meet regulatory expectations. This creates complex logistics challenges including country-specific import rules, labelling requirements, depot selection, customs clearance, documentation, tax treatment, and local storage regulations. A weak logistics setup in one market can delay an entire study.

Asia Pacific is especially important as sponsors conduct more trials in China, South Korea, Japan, India, and Australia. The ability to combine global oversight with local execution is becoming a core purchasing criterion. On 18 May 2026, Thermo Fisher Scientific’s PPD Clinical Research business opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, strengthening its ability to support cross-border clinical development and reinforcing its integrated global network spanning laboratory services, clinical research, and trial support.

Technology & Innovation

Cold-Chain Innovation for Biologics and Advanced Therapies

The increasing share of biologics, vaccines, advanced therapies, and personalised medicines in pharma pipelines is creating stronger demand for temperature-controlled clinical logistics. Unlike traditional small molecules, these products require strict cold-chain handling across refrigerated, frozen, ultra-frozen, or cryogenic conditions. Any deviation can compromise product stability, patient safety, and trial validity.

CROs and specialist logistics providers are expanding cryoshipper fleets, digital orchestration platforms, and end-to-end monitoring capabilities to strengthen traceability across global clinical supply chains. On 10 June 2026, X-Therma commercially launched its XT-NoVo and TimeSeal platform, an end-to-end biopreservation solution enabling ice-free, DMSO-free sub-zero preservation and transportation of high-value biologics, helping extend product viability and supporting more reliable cold-chain logistics for advanced therapies.

Trade & Supply Chain Dynamics

U.S. trade tariffs could increase the operating cost and planning complexity of global clinical trial supply chains, particularly where investigational medicinal products, comparators, packaging materials, temperature-controlled containers, and laboratory kits move across borders. Multi-country trials involving frequent cross-border shipments between the U.S., Europe, China, India, and other major pharma hubs face the greatest exposure, where even modest cost increases can affect procurement planning, depot strategy, and sponsor budgets.

Tariffs are unlikely to reduce clinical trial activity materially, as drug development timelines and regulatory commitments remain critical. The market impact is expected to be operational rather than demand-destructive, encouraging greater regionalisation, improved forecasting, and more resilient clinical supply models. Logistics providers with strong trade compliance, customs brokerage, bonded warehousing, and regional distribution networks are best positioned to support sponsors through this environment.

Commercial Impact

• Cost pressure: Tariffs on pharmaceutical inputs, laboratory equipment, and packaging components are raising operational costs across clinical supply chains, affecting procurement planning and sponsor budgets
• Supply chain shifts: Sponsors are accelerating supply chain diversification, regional sourcing, and localised inventory management to minimise cross-border exposure and reduce customs risk
• Depot strategy: Logistics providers are expanding regional depot networks and optimising distribution routes to maintain reliable trial operations in a more cost-sensitive and complex customs environment
• Competitive positioning: Providers with robust trade compliance capability, bonded warehousing, and deep regional logistics infrastructure are gaining outsourcing preference from sponsors managing multi-country supply complexity

Market Opportunities

Direct-to-Patient Logistics as a High-Value Growth Avenue

Direct-to-patient logistics represents one of the strongest commercial opportunities in clinical trial supply. The model is particularly attractive for rare disease, chronic disease, paediatric, elderly, and geographically dispersed patient populations, where repeated site visits reduce enrolment and retention. However, this opportunity requires validated packaging, temperature control, patient identity protection, nursing coordination, controlled returns, adherence support, and accurate documentation rather than standard parcel delivery.

In July 2026, World Courier highlighted the growing adoption of its direct-to-patient logistics services for decentralised clinical trials. The company’s network now supports clinical studies across 92 countries, with capabilities including temperature-controlled home delivery, patient sample collection, coordinated nurse visits, and compliant returns management. As hybrid trial designs become more common, direct-to-patient fulfilment is expected to transition from a specialist capability to a standard requirement in clinical supply planning.

Emerging Markets Creating Regional Depot and Local Supply Expansion Opportunities

Countries across Asia Pacific, Latin America, the Middle East, and Eastern Europe are attracting more clinical research activity due to larger patient pools, improving regulatory frameworks, and increasing healthcare investment. Sponsors frequently face gaps in reliable cold-chain infrastructure, import expertise, GMP storage, and last-mile delivery in these markets, creating an opportunity for specialist logistics providers to establish local depots, packaging and labelling capabilities, and regulatory support services.

In April 2026, Marken highlighted its continued investment in strengthening clinical trial logistics across Latin America, developing new transportation routes, enhancing regional logistics capabilities, and working closely with local authorities to streamline regulatory processes. For logistics providers, the opportunity lies in building regional capacity ahead of demand, reducing lead times, lowering import complexity, and improving supply continuity in markets that general logistics companies cannot serve effectively.

Competitive Landscape

The major players operating in the clinical trial supply and logistics market include Almac Group, Catalent, Charles River, Clinigen Limited, Eurofins Scientific, Fortrea, ICON plc, IQVIA, Labcorp, Medpace, Myonex, Parexel International Corporation, PCI Pharma Services, Pharmaron, Sharp Services LLC, Syneos Health, Thermo Fisher Scientific, and WuXi AppTec.

These companies are strengthening their market positions through M&A, capacity investment, strategic collaborations, and new service launches, with increasing focus on cold-chain capability, direct-to-patient logistics, regional depot expansion, and digital supply chain integration.

Recent Developments

• June 2026 – X-Therma commercially launched its XT-NoVo and TimeSeal platform, an end-to-end biopreservation solution enabling ice-free, DMSO-free sub-zero preservation and transportation of high-value biologics, supporting more reliable cold-chain logistics for advanced therapy clinical supply chains
• May 2026 – Parexel launched its patient-focused “From Insights to Life” campaign at the 2026 ASCO Annual Meeting, reinforcing its commitment to improving patient access through decentralised and hybrid clinical trial approaches in oncology
• April 2026 – PCI Pharma Services announced infrastructure investments exceeding US$1 billion across U.S. and European operations to strengthen sterile fill-finish and advanced drug delivery capabilities, enhancing clinical trial supply and drug product manufacturing capacity through to commercialisation
• September 2025 – DHL Supply Chain agreed to acquire SDS Rx, a specialist final-mile healthcare transportation provider, strengthening its clinical logistics capabilities in time-critical delivery for specialty pharmacies, radiopharmacies, and health system networks
• July 2025 – Almac Clinical Services completed a multi-million-dollar investment at its Craigavon headquarters, tripling secondary packaging capacity for -15 to -25 degree Celsius products, doubling ultra-low temperature storage capacity, and adding new cold-chain production rooms and packaging facilities

Frequently Asked Questions

What is driving growth in the clinical trial supply and logistics market?

Growth is driven by rising trial complexity across biologics, cell and gene therapies, and precision medicine, the rapid expansion of decentralised and hybrid trial models, and growing globalisation of clinical research requiring integrated regional supply partners with cold-chain and customs expertise.

How are trade and supply chain dynamics affecting the market?

U.S. trade tariffs on pharmaceutical inputs, packaging components, and specialised logistics materials are raising operational costs across clinical supply chains. The impact is encouraging greater regionalisation of depot networks, diversification of sourcing strategies, and investment in more resilient and flexible clinical supply models.

Who are the leading companies in the market?

Key players include Thermo Fisher Scientific, IQVIA, Almac Group, PCI Pharma Services, Parexel, World Courier, Marken, and Cryoport.

Download Sample Request

Related Reports

Cell & Gene Therapy Manufacturing Market Report 2026-2036

Pharmaceutical Packaging Market Report 2026-2036

Women’s Clinical Trials & CROs Market Report 2026-2036

About Visiongain

Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.

Media Contact

press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com